ALZN
Alzamend Neuro Inc
NASDAQ: ALZN · HEALTHCARE · BIOTECHNOLOGY
$1.14
+7.55% today
Updated 2026-04-30
Market cap
$4.03M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.67
Dividend yield
—
52W range
$1 – $6
Volume
0.1M
Alzamend Neuro Inc (ALZN) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $30614.00 | $132293.00 | $2.42M | $1.50M | $1.81M | $2.91M | $14.52M | $5.92M | $631588.00 | $4.60M |
| Cash & equivalents | $1141.00 | $4976.00 | $545000.00 | $42606.00 | $90285.00 | $1.93M | $14.06M | $5.14M | $376048.00 | $3.95M |
| Current assets | $5614.00 | $57293.00 | $2.42M | $1.50M | $1.81M | $2.91M | $14.41M | $5.84M | $455242.00 | $4.18M |
| Total liabilities | $30720.00 | $717223.00 | $96724.00 | $1.18M | $992306.00 | $899643.00 | $1.16M | $2.87M | $3.23M | $634761.00 |
| Current liabilities | $30720.00 | $717223.00 | $96724.00 | $1.18M | $992306.00 | $899643.00 | $1.16M | $2.87M | $3.23M | $634761.00 |
| Long-term debt | — | — | — | — | — | — | — | — | — | — |
| Shareholder equity | $-106.00 | $-584930.00 | $2.32M | $316915.00 | $821709.00 | $2.01M | $13.35M | $3.05M | $-2.59M | $3.97M |
| Retained earnings | $-11576.00 | $-1.58M | $-2.51M | $-7.38M | $-11.79M | $-16.83M | $-29.19M | $-44.07M | $-54.02M | $-58.54M |
| Accounts receivable | — | $1700.00 | $424351.00 | $285354.00 | $194278.00 | $16210.00 | — | — | — | — |
| Inventory | — | — | — | — | — | $-16210.00 | — | — | — | — |
| Goodwill | — | — | — | — | — | — | — | — | — | — |